Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer

E. Hernandez, N. B. Rosenshein, J. Pino y Torres, J. Villar, F. C. Grumbine, D. S. Ettinger, M. B. Dillon, J. L. Klein, S. E. Order

Research output: Contribution to journalArticlepeer-review


Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic-reactions of HOATS have been observed. Continuation of the present study seems justified.

Original languageEnglish (US)
Pages (from-to)1981-1982
Number of pages2
JournalCancer treatment reports
Issue number11
StatePublished - 1982
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this